Dianthus Therapeutics (DNTH) Long-Term Debt Issuances (2023)
Dianthus Therapeutics' quarterly Long-Term Debt Issuances came in at $377000.0 in Q1 2023.
Dianthus Therapeutics has reported Long-Term Debt Issuances for 1 years, with the latest figure at $377000.0 in Q1 2023.
- For the quarter ending Q1 2023, Long-Term Debt Issuances changed N/A year-over-year to $377000.0; the trailing twelve-month figure through Dec 2023 stood at $377000.0 (changed N/A YoY), and the FY2023 full-year result was $377000.0, changed N/A from the prior year.
- Long-Term Debt Issuances for Q1 2023 stood at $377000.0.
- The five-year high for Long-Term Debt Issuances was $377000.0 in Q1 2023, with the low at $377000.0 in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Dianthus Therapeutics | 4.02 Bn | 3.62 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 377,000.00 |
| Mar 31, 2023 | 377,000.00 |